Edwards Lifesciences Corp — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Edwards Lifesciences reported Q3 2026 sales of $1.715B (10.5% growth; 11.2% constant currency), exceeding expectations, with TAVR at $1.241B (8.0% growth) and TMTT at $209.5M (44.3% growth). Management raised full-year sales growth guidance to 11.5% from 10–11%, TAVR growth to 9.0–9.5% from 8–9%, TMTT guidance to $780–$790M, and adjusted EPS to $2.97–$3.05 (from $2.95–$3.05), representing 18% growth at midpoint. Recent regulatory approvals (PASCAL Precision tricuspid, SAPIEN M3 RESILIA, AUTUS pediatric valve) and strong clinical trial data (PROGRESS trial in moderate aortic stenosis) support momentum.
Why this rating
Modest upside beat and guidance raise signal healthy mid-single-digit organic growth. TMTT growth of 44% is notable but from small base ($209M = 0.5% of market cap). Relative to $45.9B market value, incremental $30–50M annual guidance beat is ordinary, not transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.